Mesenkia Therapeutics AB
559443-7021ActiveDeveloping novel antibodies to treat aggressive brain cancer glioblastoma.
Oversigt
- 2
- Medarbejdere
- 0 SEK
- Omsætning
- 2023
- Grundlagt
Beskrivelse
Mesenkia is a pre-clinical biotechnology company focused on developing breakthrough therapies for glioblastoma, an aggressive form of brain cancer. The company specializes in creating next-generation biological drug candidates, specifically single domain antibodies. Their scientific foundation stems...
Tags
Nøgleord
Virksomhedsoplysninger
- Branche
- Annan naturvetenskaplig och teknisk forskning och utveckling
- Juridisk form
- Aktiebolag
- Momsnummer
- SE559443702101
Beslutningstagere
Ingen beslutningstagere fundet endnu
Lignende virksomheder
20 lignende virksomheder i FunnelfeedrOblique Therapeutics AB (publ)
10–19 medarbejdereInnovative biotech developing breakthrough antibodies using the AbiProt platform.
Sang Biotech AB
0 medarbejdereDeveloping novel antibody therapeutics for kidney and cardiovascular diseases.
Affibody Medical AB
Developing next-generation radiopharmaceuticals using proprietary Affibody platform.
PILA PHARMA AB
1–4 medarbejdereClinical stage biotech developing an oral obesity and diabetes treatment.
Affibody AB
50–99 medarbejdereDeveloping next-generation radiopharmaceuticals using proprietary Affibody technology.
Udforsk mere
Spørgsmål om Mesenkia Therapeutics AB
Vil du se Funnelfeedr i aktion?
Book en gratis demo og opdag, hvordan Funnelfeedr hjælper dig med at finde og konvertere dine ideelle kunder.
Book en demo